Team:LZU-CHINA/Human Practices

C & I
Social survey Part.1 Part.2 Part.3 Part.4 Part.5 References
How should we carry out human practice, how to use human practice to improve our experimental design? This is an urgent problem that has plagued our team. The core of human practice is to improve the experiment through continuous practice and work. Therefore, we must improve and optimize our experimental design and experimental program through continuous communication and discussion, social investigation and social work.
Communication and interview

CRISPR conference

Fig.5. Discussion on experimental issues in online conference of CRISPR
At the end of the experiment, the LZU-CHINA team communicate with multiple teams through online meetings at the CRISPR conference. Our partner NEFU_China also answered some questions that have been plagued our experiments.
Our team originally planned to serially express RfxCas13d and sgRNA on lentivirus vector to target the cleavage of hACE2 mRNA in 293T stable transfer conductor. NEFU_China recommended that direct repeats of 30nt and 36nt be selected between the spacers when sgRNAs were expressed in tandem. The valuable suggestions of NEFU_China gave us great help.

Social survey
How should we carry out human practice, how to use human practice to improve our experimental design?
This is an urgent problem that has plagued our team. The core of human practice is to improve the experiment through continuous practice and work. Therefore, we must improve and optimize our experimental design and experimental program through continuous communication and discussion, social investigation and social work.
Questionnaire survey

Part.1 Survey of public intention

Facing the global novel coronavirus pandemic, LZU-CHINA team is determined to provide a novel coronavirustreatment for novel coronavirus pneumonia through this experimental project. At the beginning of our project design, according to the content of our project, we released a questionnaire to the public through online and offline channels to investigate the public ' s understanding of the novel coronavirus, the attitude of our project and the understanding of RNA editing technology.
Fig.6. LZU-CHINA Members are distributing questionnairs

Part.2 Source of questionnaire

Finally, We collected 590 questionnaires from people from all walks of life in all ages. From the results of our questionnaire, we know that nearly 70% of the answers are composed of people aged 18 to 55. Among them, 87% of respondents had at least received high school education, and their work was very different.

Part.3 Understanding of existing treatment methods

The survey showed that the public did not have enough confidence in the cure of novel coronavirus pneumonia based on the existing vaccine drugs, but had great confidence in the development of specific drugs to cure novel coronavirus pneumonia. Therefore, it is particularly important to develop a novel coronavirusanti-virus prevention method that is trusted by the public. The results also confirmed our determination to develop novel coronavirustreatments.

Part.4 Understanding of RNA Editing/CRISPR Technology

The survey data showed that only 20% of the sample population thought they knovel coronavirusenough RNA editing technology. However, when it comes to the treatment of diseases using RNA editing technology, 74% of the sample population is willing to accept this therapy. Among the 25% of the sample population who were unwilling to accept this technology, 55% were unwilling to accept the application of this technology in clinic because they did not understand RNA editing technology. At the same time, The biggest concern is the security involved in RNA editing, which is also one of the most concerned issues when any novel coronavirustechnology comes out.
From these reactions, we can infer that the public still lacks knowledge and education about RNA editing technology. These responses also encourage us to carry out relevant social education and popularize novel coronavirustherapeutic technologies such as synthetic biology to students of different ages, such as RNA editing technology. This is also the starting point for the educational activities of the LZU-CHINA team.

Part.5 Acceptance of therapy

In the questionnaire, we introduced that the LZU-CHINA team will treat novel coronavirus pneumonia(COVID-19) through CRISPR-Cas13d system technology. We designed some questions to investigate the acceptability of the sample population for CRISPR-Cas13d system technology in treating COVID-19. 85% of the sample population were willing to accept this system technology, while 15% of the sample population were unwilling to accept this technology, mainly because they were not familiar with the system technology and worried about its security. If they reached a critical high-risk state, 75% of the sample population were willing to accept CRISPR-Cas13 system technology as treatment. At the same time, we investigated the public’ s choices of the two therapeutic tools — Adeno-Associated Virus/Lentivirus. The survey results showed that 69% of the sample population were more willing to choose the Adeno-Associated virus with safety certified by the EU, so we chose the Adeno-Associated virus that the public was more willing to accept as our therapeutic vector. In the selection of our clinical treatment, we introduced to the public the strategy of atomization inhalation delivery of drugs (CRISPR-Cas13d system) to the lungs (drugs mainly act on the lung tissues mainly infected by novel coronavirus to improve its safety). 85% of the sample population expressed willingness to accept this clinical treatment.
Through extensive social surveys, we are fully aware of public awareness of the novel coronavirus and attitudes towards the direction of the LZU-CHINA project. This not only helps shape our experiment design, but also provides direction and content for other social activities in the future.
References
[1]Zhang Ruifeng,Wu Yingli,Zhao Meng,Liu Chuanxu,Zhou Lin,Shen Shaoming,Liao Shihua,Yang Kun,Li Qingyun,Wan Huanying. Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells.[J]. American journal of physiology. Lung cellular and molecular physiology,2009,297(4):